Mazdutide (Xinermei)
Also known as: Xinermei
Browse our Mazdutide (Xinermei) articles and comparisons. Start with the drug explainer for the mechanism and trial evidence, or choose a comparison below.
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Innovent Biologics (licensed from Eli Lilly) |
| Mechanism | Dual agonist — GLP-1 + glucagon receptors |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~14–18% (Chinese Phase 3 program) |
| Status | Approved in China (Xinermei) 2025; US Phase 2 ongoing |
Drug explainer
What Is Mazdutide (Xinermei)? The First GLP-1/Glucagon Drug Approved in China →Mazdutide is approved in China. Chinese Phase 3 and US Phase 2 studies describe different doses, populations and outcomes.
Mazdutide (Xinermei) compared
Comparisons involving Mazdutide (Xinermei), with the limits of comparing separate trials.
Mazdutide vs Retatrutide: Dual vs Triple Agonist Data 2026
How the triple agonist retatrutide compares to the dual agonist mazdutide on weight loss, diabetes, and liver fat data.
Updated September 8, 2026
Mazdutide vs Tirzepatide: GLP-1/Glucagon vs GLP-1/GIP Compared
Different dual-agonist mechanisms, trial populations and approvals. Separate GLORY and SURMOUNT results do not establish a head-to-head winner.
Updated September 8, 2026
Mazdutide vs Survodutide: Two GLP-1/Glucagon Dual Agonists Compared
GLORY and SYNCHRONIZE results, liver endpoints and availability. Neither separate trials nor low discontinuation prove a tolerability advantage.
Updated September 8, 2026
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.